Disease severity-based evaluation of utility weights for lung cancer-related health states in Korea

Kim, Eun-Jung; Ock, Minsu; Kim, Kyu-Pyo; Jung, Nuri; Lee, Hyeon-Jeong; Kim, Seon-Ha; Jo, Min‐Woo

doi:10.1186/s12885-018-4960-y

Cited by 5 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer subtypes comprised one study in squamous cell lung cancer [42], three studies in NSCLC [28,43,44], and one study in general lung cancer (n = 1) [45]. Four studies reported HSUVs derived from indirect methods [28,[43][44][45], and one from direct methods [42]. Studies by Wolff et al [44] and Iyer et al [28] that only reported HSUVs for early disease or late disease are summarized in Online Resource 4.…”

Section: Lung Cancermentioning

confidence: 99%

“…d Kim [36]: SG, hypothetical health states, general population separate study by Shen et al [43], HSUVs (based on EQ-5D-3L) in patients with NSCLC resulted in a disutility of − 0.095 for stage IV vs III. In the third study, Kim et al [42] used SG to elicit HSUVs in adults from the general population in Korea, revealing that the largest disutility occurred for stage IV vs I (− 0.350) compared with stage IV vs II (− 0.250) and stage IV vs III (− 0.105). Consistent results were observed in this study among subgroups based on gender, age, education level, occupation, monthly income, hospitalization, and morbidity.…”

Section: Lung Cancermentioning

confidence: 99%

“…Five studies assessed HSUVs in lung cancer from patients with the disease or individuals without cancer. Lung cancer subtypes comprised one study in squamous cell lung cancer [ 42 ], three studies in NSCLC [ 28 , 43 , 44 ], and one study in general lung cancer ( n = 1) [ 45 ]. Four studies reported HSUVs derived from indirect methods [ 28 , 43 – 45 ], and one from direct methods [ 42 ].…”

Section: Patient Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

Health state utility values by cancer stage: a systematic literature review

Pourrahmat¹,

Kim

Kansal

et al. 2021

Eur J Health Econ

View full text Add to dashboard Cite

Objectives Cancer diagnoses at later stages are associated with a decrease in health-related quality of life (HRQOL). Health state utility values (HSUVs) reflect preference-based HRQOL and can vary based on cancer type, stage, treatment, and disease progression. Detecting and treating cancer at earlier stages may lead to improved HRQOL, which is important for value assessments. We describe published HSUVs by cancer type and stage. Methods A systematic review was conducted using Embase, MEDLINE®, EconLit, and gray literature to identify studies published from January 1999 to September 2019 that reported HSUVs by cancer type and stage. Disutility values were calculated from differences in reported HSUVs across cancer stages. Results From 13,872 publications, 27 were eligible for evidence synthesis. The most frequent cancer types were breast (n = 9), lung (n = 5), colorectal (n = 4), and cervical cancer (n = 3). Mean HSUVs decreased with increased cancer stage, with consistently lower values seen in stage IV or later-stage cancer across studies (e.g., − 0.74, − 0.44, and − 0.51 for breast, colorectal, and cervical cancer, respectively). Disutility values were highest between later-stage (metastatic or stage IV) cancers compared to earlier-stage (localized or stage I–III) cancers. Conclusions This study provides a summary of HSUVs across different cancer types and stages that can inform economic evaluations. Despite the large variation in HSUVs overall, a consistent decline in HSUVs can be seen in the later stages, including stage IV. These findings indicate substantial impairment on individuals’ quality of life and suggest value in early detection and intervention.

show abstract

Section: Lung Cancermentioning

confidence: 99%

Section: Lung Cancermentioning

confidence: 99%

Section: Patient Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Health state utility values by cancer stage: a systematic literature review

Pourrahmat¹,

Kim

Kansal

et al. 2021

Eur J Health Econ

View full text Add to dashboard Cite

show abstract

“…The remaining 24 studies were excluded from subsequent analyses . Among the excluded studies, four did not measure HRQoL in patients [72,77,81,82], nine did not use valuation by members of the general public [59,60,63,69,71,72,74,81,82], 11 did not use a choice-based method for valuation [59, 63, 65, 67-71, 74, 76, 81], and nine had missing data on one or more of these items [61,62,64,66,73,75,[78][79][80].…”

Section: Critical Appraisalmentioning

confidence: 99%

Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer

2020

View full text Add to dashboard Cite

Background Using appropriate health state utility values (HSUVs) is critical for economic evaluation of new lung cancer interventions, such as low-dose computed tomography screening and immunotherapy. Therefore, we provide a systematic review and meta-analysis of community-and choice-based HSUVs for lung cancer. Methods On 6 March 2017, we conducted a systematic search of the following databases: Embase, Ovid MEDLINE, Web of Science, Cochrane CENTRAL, Google Scholar, and the School of Health and Related Research Health Utility Database. The search was updated on 17 April 2019. Studies reporting mean or median lung cancer-specific HSUVs including a measure of variance were included and assessed for relevance and validity. Studies with high relevance (i.e. community-and choicebased) were further analysed. Mean HSUVs were pooled using random-effects models for all stages, stages I-II, and stages III-IV. For studies with a control group, we calculated the disutility due to lung cancer. A sensitivity analysis included only the methodologically most comparable studies (i.e. using the EQ-5D instrument and matching tariff). Subgroup analyses were conducted by time to death, histology, sex, age, treatment modality, treatment line, and progression status. Results We identified and analysed 27 studies of high relevance. The pooled HSUV was 0.68 (95% confidence interval [CI] 0.61-0.75) for all stages, 0.78 (95% CI 0.70-0.86) for stages I-II, and 0.69 (95% CI 0.65-0.73) for stages III-IV (p = 0.02 vs. stage I-II). Heterogeneity was present in each pooled analysis (p < 0.01; I 2 = 92-99%). Disutility due to lung cancer ranged from 0.11 (95% CI 0.05-0.17) to 0.27 (95% CI 0.18-0.36). In the sensitivity analysis with the methodologically most comparable studies, stage-specific HSUVs varied by country. Such studies were only identified for Canada, China, Spain, the UK, the USA, Denmark, Germany, and Thailand. In the subgroup analysis by time to death, HSUVs for metastatic non-small-cell lung cancer ranged from 0.83 (95% CI 0.82-0.85) at ≥ 360 days from death to 0.56 (95% CI 0.46-0.66) at < 30 days from death. Among patients with metastatic non-small-cell lung cancer, HSUVs were lower for those receiving third-or fourth-line treatment and for those with progressed disease. Results of subgroup analyses by histology, sex, age, and treatment modality were ambiguous. Conclusions The presented evidence supports the use of stage-and country-specific HSUVs. However, such HSUVs are unavailable for most countries. Therefore, our pooled HSUVs may provide the best available stage-specific HSUVs for most countries. For metastatic non-small-cell lung cancer, adjusting for the decreased HSUVs in the last year of life may be considered, as may further stratification of HSUVs by treatment line or progression status. If required, HSUVs for other health states may be identified using our comprehensive breakdown of study characteristics.

show abstract

“…The weights as follows: age 55–59, 0.942; age 60–64, 0.944; age 65–69, 0.916; age 70–74, 0.880; age 75–79, 0.887; age ≥ 80, 0.829. The utility weights of health states in each cancer stage were obtained from the utility study for lung cancer-related health states in Korea ( Table 1 ) [ 31 ].…”

Section: Methodsmentioning

confidence: 99%

Cost Utility Analysis of a Pilot Study for the Korean Lung Cancer Screening Project

et al. 2022

Self Cite

View full text Add to dashboard Cite

The aim of this study was to evaluate the cost utility of a pilot study of Korean lung cancer screening project. Materials and MethodsWe constructed a Markov model consisting of 26 states based on the natural history of lung cancer according to the Surveillance, Epidemiology, and End Results summary stage (localized, regional, distant). In the base case, people aged 55-74 years were under consideration for annual screening. Costs and quality-adjusted life years were simulated to calculate the incremental cost utility ratio. Sensitivity analyses were performed on the uncertainty associated with screening target ages, stage distribution, cost, utility, mortality, screening duration, and discount rate. ResultsThe base case (US$25,383 per QALY gained) was cost-effective compared to the scenario of no screening and acceptable considering a willingness-to-pay threshold of US$27,000 per quality-adjusted life years gained. In terms of the target age of screening, the age between 60 and 74 years was the most cost-effective. Lung cancer screening was still cost-effective in the sensitivity analyses on the cost for treatment, utility, mortality, screening duration, and less than 5% discount rates, although the result was sensitive to a rise in positive rates or variation of stage distribution. ConclusionOur results showed the cost-effectiveness of annual low-dose computed tomography screening for lung cancer in high-risk populations.

show abstract

Disease severity-based evaluation of utility weights for lung cancer-related health states in Korea

Cited by 5 publications

References 28 publications

Health state utility values by cancer stage: a systematic literature review

Health state utility values by cancer stage: a systematic literature review

Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer

Cost Utility Analysis of a Pilot Study for the Korean Lung Cancer Screening Project

Contact Info

Product

Resources

About